Welcome to our dedicated page for Edwards Lifesciences SEC filings (Ticker: EW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Edwards Lifesciences Corporation (NYSE: EW) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a structural heart medical device manufacturer. These filings, sourced from the SEC’s EDGAR system, include current reports on material events, earnings announcements, capital markets activity and other items relevant to shareholders and analysts.
Edwards Lifesciences uses Form 8‑K to report developments such as quarterly financial results, financial guidance updates, leadership transitions, accelerated share repurchase agreements and legal or regulatory matters. Recent 8‑K filings, for example, describe third‑quarter financial results, a planned chief financial officer transition, an accelerated share repurchase agreement and legal proceedings related to the Federal Trade Commission’s successful motion to block the proposed acquisition of JenaValve Technology.
In addition to current reports, investors typically review Edwards’ annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which provide detailed information on its structural heart portfolio, risk factors, research and development spending, and segment performance across transcatheter aortic valve replacement, transcatheter mitral and tricuspid therapies and surgical heart valves. Proxy statements on Schedule 14A and beneficial ownership or insider trading reports on Forms 3, 4 and 5 offer further insight into governance and executive equity activity.
Stock Titan enhances these filings with AI‑powered summaries that explain key points in accessible language, highlight important changes from prior periods and help readers interpret complex sections. Real‑time updates ensure that new Edwards Lifesciences filings appear promptly, while AI‑generated overviews of 10‑K, 10‑Q and Form 4 documents can assist users in quickly understanding the implications of lengthy disclosures and insider transactions without replacing their own review of the original filings.
Edwards Lifesciences Corp Chief Financial Officer Scott B. Ullem exercised employee stock options to acquire 13,000 shares of common stock at $59.2567 per share. These options related to an award exercisable since May 8, 2020 and expiring on May 7, 2026, and the filing shows this option position is now fully exercised.
To cover tax obligations, the company withheld 11,131 shares at $82.91 and 620 shares at $83.98, reported as tax-withholding dispositions rather than open-market sales. After these transactions, Ullem directly owns 40,948 shares and indirectly holds 266,318 shares of common stock through a trust.
Edwards Lifesciences CEO Bernard J. Zovighian reported routine share dispositions mainly related to gifts and tax withholding. On May 5, 2026, he made two bona fide gifts of common stock, transferring 523 shares from a trust and 523 shares from his direct holdings, both at a stated price of $0.00 per share, reflecting that no consideration was received. Earlier, on May 3, 2026, 515 shares were disposed of at $83.98 per share to satisfy tax obligations, a tax-withholding disposition rather than an open-market sale. Following these transactions, he continues to hold 80,257.6499 direct shares, 12,039.5511 shares indirectly through a trust, and 3,733.5603 shares indirectly in a 401(k) plan.
Edwards Lifesciences Corp CVP, TAVR Daniel J. Lippis reported option exercises, tax withholding, and open-market sales of company stock. On May 1, 2026, he exercised employee stock options for 1,019 shares at $59.2567 per share and sold 1,000 shares at $82.9889 plus 19 shares at $83.9880. On May 4, 2026, he exercised options for another 1,019 shares at $59.2567 and sold 1,019 shares at $83.98. A separate 252-share disposition on May 3, 2026 covered tax obligations. After these transactions, he directly held about 33,681.9103 shares of Edwards Lifesciences common stock. The filing notes all reported trades were effected under a pre-arranged Rule 10b5-1 trading plan.
Edwards Lifesciences Corp executive Daveen Chopra reported a routine tax-related share disposition. On the transaction date, 282 shares of common stock were withheld at $83.98 per share to cover tax obligations, leaving Chopra with 31,919 shares of Edwards Lifesciences common stock held directly after the transaction.
Edwards Lifesciences Corp executive Donald E. Bobo Jr., Corporate Vice President of Strategy and Corporate Development, reported routine share updates and a small tax-related disposition of company stock. The filing shows a tax-withholding disposition of 469 shares of common stock at $83.98 per share, leaving him with 20,797.2532 shares held directly.
The filing also reports indirect holdings of 121,756 common shares held by a trust and 38,969.5756 shares represented in a 401(k) plan account, based on the plan administrator’s most recent statement. Overall, this Form 4 reflects mainly administrative updates and tax withholding rather than open-market buying or selling.
Edwards Lifesciences Corporation filed a Form 8-K announcing that Theodora (“Doretta”) Mistras has been appointed Corporate Vice President and Chief Financial Officer, effective May 29, 2026, succeeding Scott B. Ullem. The company highlights her prior experience as CFO of Viatris and senior roles in healthcare investment banking.
Under her offer letter, Mistras will receive a base salary of $925,000, a target annual bonus of at least 100% of base salary under the Edwards Lifesciences Incentive Plan, and a $2,013,000 sign-on bonus subject to pro-rata repayment if she departs within 24 months in certain circumstances. She will also receive $8,000,000 in restricted stock units vesting over three years, an initial 2026 annual equity award valued at $4,500,000, severance protections of at least one times salary and target bonus plus a pro-rated bonus and $50,000 in outplacement benefits, and reimbursement of up to $15,000 in legal fees and relocation costs.
Edwards Lifesciences Corporation submitted a Form 144 notice relating to proposed sales tied to an employee stock option exercise on 05/04/2026, identified as a broker payment for cashless exercise. The filing also lists prior sales by Daniel J. Lippis on 03/11/2026 (87,004 shares), 04/06/2026 (82,523 shares) and 05/01/2026 (84,585 shares).
Edwards Lifesciences Corp ownership disclosure: Vanguard Capital Management reports beneficial ownership of 43,477,533 shares of Common Stock, representing 7.54% of the class as reported. The filing shows 5,749,741 shares with sole voting power and 43,477,533 shares with sole dispositive power. The statement attributes holdings to Vanguard-related entities and is signed by a Vanguard official.
Edwards Lifesciences reported strong first quarter 2026 results, with net sales of $1.65 billion, up 16.7% year over year, and constant currency sales growth of 12.7%. GAAP diluted EPS was $0.66 and adjusted EPS was $0.78, reflecting solid operational performance.
TAVR sales rose 14.4% to $1.20 billion and TMTT sales reached $173 million, both supported by broader adoption of SAPIEN, EVOQUE, PASCAL and SAPIEN M3 therapies. Surgical sales grew 10.1% to $276 million, driven by RESILIA-based products and new launches.
The company raised its 2026 constant currency sales growth guidance to 9%–11%, TAVR growth guidance to 7%–9%, and adjusted EPS guidance to $2.95–$3.05. Gross margin remained high at 78.0% (78.2% adjusted). Edwards ended the quarter with about $2.4 billion in cash, $600 million of total debt, and completed a $500 million accelerated share repurchase.
Edwards Lifesciences CVP and Chief Financial Officer Scott B. Ullem exercised employee stock options for 13,000 shares of common stock at an exercise price of $59.2567 per share and sold 13,000 shares in open-market transactions. The sales occurred in two tranches at weighted average prices of $80.4963 and $79.7866 per share under a pre-arranged Rule 10b5-1 trading plan adopted on July 29, 2025. After these transactions, he holds 39,699 shares directly and 266,318 shares indirectly through a trust, resulting in a net reduction of 13,000 shares in his position.